BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TH-302: Preliminary Phase I data

Preliminary data from 11 evaluable patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in the dose-escalation portion of an open-label, U.S. Phase I trial showed that there were no DLTs...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >